Bristol-Myers bets biomarkers will show who needs "bigger hammer"

With EULAR in full swing in Madrid, much of the focus, as in other therapeutic areas, has been on the use of biomarkers to guide personalized treatment options.

It’s an area that particularly concerns Brian Gavin, vice president of the Orencia (abatacept) program at New York-based major Bristol-Myers Squibb (NYSE: BMY).

Dr Gavin is also focused on getting to patients early in order to disrupt the progression of rheumatoid arthritis, a life-changing disease which, if left untreated, leads to functional disability, pain and premature mortality.